Results Healthcare Appoints Industry Veteran Nick Hyde as Managing Director
Healthcare corporate finance and strategy specialist, Results Healthcare, has announced the appointment of life sciences industry veteran Nick Hyde as Managing Director, where he joins the dedicated team of healthcare corporate finance professionals servicing the practice’s growing client base.
With more than 25 years of pharmaceutical and life sciences business experience, Nick spent 15 years as head of various manufacturing and business departments at ICI. As the ICI business transitioned, he became Director of Operations for Zeneca’s Life Science Molecules business and then spent 2 years as Vice President of Avecia Pharmaceuticals, culminating in having responsibility for more than 700 manufacturing, R&D and commercial staff across four sites in the UK and overseas, and responsibility for integrating acquisitions in North America.
Nick then became Global Business Leader of the Dowpharma business unit of The Dow Chemical Company, and was a key member of the team which successfully divested the UK arm of the business. During this 6-year period, he led the consolidation of all of Dow Chemical’s service and technology offerings to the pharmaceutical and biotech industries, which included the creation of two US-based Biotech start ups.
A graduate in engineering from Cambridge University, since leaving Dow in 2008 Nick has worked on a number of major asset divestments for pharmaceutical clients in addition to his work with med tech start up companies in the Cambridge area. He is currently a director of Inotec AMD Ltd and Chairman of The Diabetic Boot Company.
Nick’s industry leadership was recognised by his election to the Board of Governors of the US trade organisation, SOCMA, in 2001 and 2002.
“Nick’s industry experience, depth of knowledge and leadership skills will prove invaluable as we continue our ambitious business growth,” commented Results Healthcare Managing Director, Kevin Bottomley. “Having worked with Nick previously, I am well aware of the strengths that he brings to our team and am excited that he has chosen to join us at this stage in the company’s development.”
“Results Healthcare gives me the opportunity to continue to work with clients in both the pharmaceutical and med tech sectors, helping them to re-shape their capabilities, manage strategic change, raise the funding they need to bring exciting new products to market and ultimately find the right corporate partners,” added Nick Hyde “Doing this within a large group like Results and helping to build on the strong franchise of the business is an exciting new challenge for me.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance